A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72854
Title:
A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis.
Authors:
Baka, Sofia; Clamp, Andrew R; Jayson, Gordon C ( 0000-0002-8515-8944 )
Abstract:
Angiogenesis plays an important role in the formation of new blood vessels and is crucial for tumour development and progression. Imbalance between pro- and antiangiogenesis factors regulates the biological process of angiogenesis. The best characterised of the proangiogenic factors and the most potent is vascular endothelial growth factor (VEGF). The binding of VEGF to one of its transmembrane tyrosine kinase receptors, which are predominantly found on endothelial cells, results in receptor dimerisation, activation and autophosphorylation of the tyrosine kinase domain. This triggers a cascade of complex downstream signalling pathways. Several strategies targeting the VEGF signalling pathway have been developed. These include neutralising antibodies to VEGF (bevacizumab) or VEGF receptors (VEGFRs) (DC101), soluble VEGFR/VEGFR hybrids (VEGF-Trap), and tyrosine kinase inhibitors of VEGFRs (BAY43-9006, SU11248, ZD6474, AZD2171, PTK/ZK and others). Several of these agents are now being investigated in clinical trials.
Affiliation:
Christie Hospital, Manchester, M20 4BX, UK. bakasofia@hotmail.com
Citation:
A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. 2006, 10 (6):867-76 Expert Opin. Ther. Targets
Journal:
Expert Opinion on Therapeutic Targets
Issue Date:
Dec-2006
URI:
http://hdl.handle.net/10541/72854
DOI:
10.1517/14728222.10.6.867
PubMed ID:
17105373
Type:
Article
Language:
en
ISSN:
1744-7631
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorBaka, Sofia-
dc.contributor.authorClamp, Andrew R-
dc.contributor.authorJayson, Gordon C-
dc.date.accessioned2009-07-07T15:16:35Z-
dc.date.available2009-07-07T15:16:35Z-
dc.date.issued2006-12-
dc.identifier.citationA review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. 2006, 10 (6):867-76 Expert Opin. Ther. Targetsen
dc.identifier.issn1744-7631-
dc.identifier.pmid17105373-
dc.identifier.doi10.1517/14728222.10.6.867-
dc.identifier.urihttp://hdl.handle.net/10541/72854-
dc.description.abstractAngiogenesis plays an important role in the formation of new blood vessels and is crucial for tumour development and progression. Imbalance between pro- and antiangiogenesis factors regulates the biological process of angiogenesis. The best characterised of the proangiogenic factors and the most potent is vascular endothelial growth factor (VEGF). The binding of VEGF to one of its transmembrane tyrosine kinase receptors, which are predominantly found on endothelial cells, results in receptor dimerisation, activation and autophosphorylation of the tyrosine kinase domain. This triggers a cascade of complex downstream signalling pathways. Several strategies targeting the VEGF signalling pathway have been developed. These include neutralising antibodies to VEGF (bevacizumab) or VEGF receptors (VEGFRs) (DC101), soluble VEGFR/VEGFR hybrids (VEGF-Trap), and tyrosine kinase inhibitors of VEGFRs (BAY43-9006, SU11248, ZD6474, AZD2171, PTK/ZK and others). Several of these agents are now being investigated in clinical trials.en
dc.language.isoenen
dc.subject.meshAngiogenesis Inhibitors-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshHumans-
dc.subject.meshNeovascularization, Pathologic-
dc.subject.meshVascular Endothelial Growth Factors-
dc.titleA review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital, Manchester, M20 4BX, UK. bakasofia@hotmail.comen
dc.identifier.journalExpert Opinion on Therapeutic Targetsen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.